Success Metrics

Clinical Success Rate

100.0%

Based on 8 completed trials

Completion Rate

100%(8/8)

Active Trials

0(0%)

Results Posted

38%(3 trials)

Phase Distribution

Ph phase_2

11%

Ph not_applicable

11%

Ph phase_1

11%

Ph phase_3

11%

Ph phase_4

22%

Ph early_phase_1

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Early Phase 1First-in-human

1(14.3%)

Phase 1Safety & dosage

1(14.3%)

Phase 2Efficacy & side effects

1(14.3%)

Phase 3Large-scale testing

1(14.3%)

Phase 4Post-market surveillance

2(28.6%)

N/ANon-phased studies

1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(8)

Other(1)

Detailed Status

Completed8

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (14.3%)

Phase 11 (14.3%)

Phase 21 (14.3%)

Phase 31 (14.3%)

Phase 42 (28.6%)

N/A1 (14.3%)

Trials by Status

completed889%

unknown111%

Recent Activity

0 active trials

Showing 5 of 9

completedphase_3

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

NCT06217848

completednot_applicable

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

NCT03795701

View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials

NCT03115424Phase 3

Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy

Completed

NCT03036800Phase 4

Saxenda in Obesity Services (STRIVE Study)

Completed

NCT03885297

3mg Liraglutide for Overweight or Obesity

Completed

NCT06217848Early Phase 1

The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study

Unknown

NCT03795701Not Applicable

To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity

Completed

NCT05111912Phase 2

Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With Obesity

Completed

NCT03048578Phase 4

Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery

Completed

NCT05153590

A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland

Completed

NCT04903509Phase 1

A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide

Completed

All 9 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 9